Vaccine and drug combo for advanced fibrolamellar carcinoma
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a vaccine targeting a specific fusion protein found in fibrolamellar carcinoma, combined with two immunotherapy drugs and a glutamine blocker. It is for patients whose cancer has gotten worse despite previous treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced fibrolamellar carcinoma that cannot be removed by surgery or has spread.
- Your tumor has a specific DNA change called the DNAJB1-PRKACA fusion.
- Your cancer has worsened during or after a prior immunotherapy treatment.
- You are at least 12 years old and weigh at least 40 kg if under 18.
- You can perform daily activities with little to no help (ECOG 0-2).
- You have had no checkpoint inhibitor drugs before (like nivolumab or ipilimumab).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a personalized peptide vaccine (targeting the DNAJB1-PRKACA fusion) combined with immunotherapy drugs to treat fibrolamellar hepatocellular carcinoma (FLC) or other eligible non-FLC cancers with the same gene fusion. It aims to see whether this immune-based treatment can shrink tumors and improve outcomes safely.
This trial tests a new combination of two drugs—DRP-104 and durvalumab—to see if they can shrink or slow advanced fibrolamellar carcinoma, a rare liver cancer. It is for patients whose cancer has gotten worse even after immunotherapy treatment.
This trial tests a vaccine designed to target cancer cells with a specific genetic change (DNAJB1-PRKACA). It is for people whose fibrolamellar liver cancer or other tumors with this change are in complete remission after prior treatment, to help prevent the cancer from coming back.
This Phase 1 study tests a custom vaccine made to match a specific cancer genetic change (DNAJB1-PRKACA fusion). It’s combined with an approved immunotherapy (immune checkpoint inhibitor) to help your immune system recognize and fight the cancer. You may be considered if your cancer is advanced or has spread and you meet several blood/organ and health requirements.
This Phase 1/2 trial tests whether nivolumab combined with fluorouracil and interferon alpha can treat fibrolamellar liver cancer that cannot be safely removed with surgery. It aims to shrink or control the cancer and to see how safe the combination is.
This trial tests a combination of two immunotherapy drugs, TACE (a procedure to block blood flow to tumors), and lenvatinib (a targeted therapy) for people with liver cancer that has not responded to initial treatment. It aims to see if this combination can help shrink tumors or slow cancer growth.
Hear when a new Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.